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Background. Opioid analgesics are included in treatment guidelines for the symptomatic management of osteoarthritis (OA).
Starting with a low dose of opioid and slowly titrating to a higher dose may help avoid intolerable side eﬀects. Methods. Subjects
aged ≥40 years, with moderate to severe pain induced by OA of the hip or knee not adequately controlled by previous non-
steroidal anti-inﬂammatory drugs (NSAIDs) or paracetamol treatment, were enrolled. Subjects received OROS hydromorphone
4mg or placebo once-daily. The dose was titrated every 3-4 days in case of unsatisfactory pain control during the 4-week titration
phase. A 12 week maintenance phase followed. The primary eﬃcacy endpoint was the change in “pain on average” measured
on the Brief Pain Inventory (BPI) scale from baseline to the end of the maintenance phase. Results. 139 subjects received OROS
hydromorphone and 149 subjects received placebo. All eﬃcacy endpoints showed similar improvements from baseline to end of
study in the 2 groups. The safety results were consistent with the safety proﬁle of OROS hydromorphone. Conclusion.The study
did not meet the primary endpoint; although many subjects’ pain was not adequately controlled at inclusion, their pain may have
improved with continued paracetamol or NSAID treatment.
1.Introduction
Providing relief from chronic pain is a major worldwide
public health issue [1]. A systematic review of 4 studies
that used the International Association for the Study of
Pain (IASP) deﬁnition for chronic pain found that the
prevalence of pain >3 months duration ranged from 11.5%
to 55.2%; 3 studies involved the general population, and
1 study assessed patients in primary care [2]. A study of
the general population in 15 European countries and Israel
estimated that the point prevalence of chronic nonmalignant
pain ranged from 12% to 30%; 40% of patients with chronic
pain were not satisﬁed with the treatment they received [3].
Nearly 50% of individuals with chronic severe pain do not
have their pain under control [4].
Osteoarthritis (OA) is the most common form of joint
disease. The prevalence of OA increases with age; more than
75% of subjects over 70 years of age have radiologically
detectable OA changes [5]. Clinical symptoms such as pain,
joint stiﬀness, and joint deformities are associated with OA2 Pain Research and Treatment
([6–8]); OA leads to considerable restriction of mobility,
which can progress to disability. OA was recently estimated
to aﬀect nearly 27 million adults in the United States [9].
There are currently no cures for OA, and treatment is aimed
at managing the associated symptoms; treatments include
reducingjointpainandstiﬀness,maintainingandimproving
joint mobility, reducing physical disability and handicap,
improving health-related quality of life (HRQoL), limiting
the progression of joint damage, and educating patients
about the nature of the disorder and its management [10].
Therefore, OA is a major sociomedical problem with high
prevalence and signiﬁcant associated costs.
Opioid therapy is increasingly being used for the treat-
ment of chronic noncancer pain although long-term opioid
use remains controversial owing to concerns about long-
term eﬀectiveness and safety, particularly the risk of devel-
oping tolerance, dependence, or abuse ([11–17]). Common
opioid side eﬀects include nausea, vomiting, constipation,
itching, and sedation; with the exception of constipation,
these generally diminish over time [13]. Opioid side eﬀects
should be anticipated and treated as appropriate [18].
The use of opioid analgesics is included in treatment
guidelinesforthesymptomaticmanagementofOAofthehip
or knee; weak opioids may be considered for the treatment
of refractory pain where other pharmacological agents have
been ineﬀective, whilst strong opioids should only be used
for managing severe chronic pain in exceptional circum-
stances [10]. The eﬀects on pain and function and the safety
of oral or transdermal opioids compared with placebo or no
intervention in patients with OA of the hip or knee was the
subject of a recent Cochrane review [19]. Overall, opioids
were more eﬀective than control interventions in terms of
pain relief and improvement of function, irrespective of the
type or analgesic potency of the opioid. However, patients
receivingopioidsmorefrequentlyexperiencedadverseevents
(AEs) compared with patients receiving control interven-
tions.
Guidelines on the use of opioids for chronic pain have
recommended the use of controlled release formulations and
scheduled regimens ([20–22]). Controlled-release opioid
formulations aim to maintain sustained opioid plasma
concentrations with minimal ﬂuctuations between doses,
oﬀering sustained pain relief over 24h with manageable side
eﬀects [23]. Starting with a low dose of opioid and slowly
titratingtoahigherdosemaybebeneﬁcialforavoidingintol-
erable side eﬀects. There is some limited evidence that this
approachmaybeadvantageouswhenstartingtreatmentwith
oxycodone, oxymorphone, or hydromorphone ([24–27]).
OROS hydromorphone (Janssen Pharmaceutica NV,
Beerse, Belgium) is a unique, once-daily opioid formula-
tion that uses the patented OROS Push-Pull technology
(ALZA, Vacaville, Calif, USA) to deliver hydromorphone
with continuous, monophasic drug release over 24 hours,
with the aim of providing consistent, longlasting analgesia
([28, 29]). In Europe, OROS hydromorphone is indicated
for the treatment of moderate-to-severe chronic pain that
needs continuous treatment and is currently available in 5
strengths: 4mg, 8mg, 16mg, 32mg, and 64mg [28]. Not all
dosage strengths may be available in all countries.
Here we report the results of the hydromorphone for
OA pain (HOP) trial. In this placebo-controlled trial,
subjects who were randomised to treatment with OROS
hydromorphone hydrochloride were started on the lowest
dose of 4mg once daily; their dose was titrated every 3-4
days in the event of unsatisfactory pain control during
the 4-week titration phase. The rationale for using a lower
starting dose of 4mg is that it may induce tolerance to the
adverse eﬀects of the opioid and therefore may reduce the
number of AEs and consequently the dropout rate. The
primary objective was to compare the analgesic eﬀect of
ﬂexibly titrated OROS hydromorphone hydrochloride and
placebo in subjects with moderate-to-severe pain induced
by OA of the hip or knee that had not been adequately
controlled by previous treatment with non-steroidal anti-
inﬂammatory drugs (NSAIDs) or paracetamol measured by
“pain on average” on the brief pain inventory (BPI) scale.
Secondary objectives included assessing the dropout rate
due to AEs, the eﬀect of treatment on subjects’ functionality
using the total score of the Western Ontario and McMaster
Universities (WOMAC) OA index, the eﬀect of treatment on
pain using the pain subscales of the WOMAC OA index and
the HRQoL instrument short form (SF)-36 and pain-related
items measured on the BPI scale, and the overall safety and
tolerability of the drug. Secondary objectives analysed on an
exploratory basis included assessing the eﬀect of treatment
on subjects’ HRQoL using all other subscales, except pain,
of the instrument SF-36, the eﬀect of treatment on subjects’
functional impairment and stiﬀness using these subscales of
the WOMAC OA index, the eﬀect of treatment on subjects’
quality of sleep using a medical outcome study (MOS) sleep
subscale score, and the dropout rate due to ineﬃcacy.
2.SubjectsandMethods
The study protocol and amendments were reviewed by
the appropriate Independent Ethics Committee (IEC) or
Institutional Review Board (IRB) for each study centre.
The study was conducted in accordance with the ethical
principles that have their origin in the Declaration of
Helsinki (amended Edinburgh 2000, with notes of clari-
ﬁcation Washington 2002 and Tokyo, 2004) and that are
consistent with good clinical practices (GCP) and applicable
regulatory requirements.
Subjects gave written informed consent before entering
the study.
2.1. Study Design, Population, and Treatments. This phase
IIIb, multicentre, randomised, parallel-group, placebo-
controlled, double-blind study was carried out at 18 sites
in four European countries (Czech Republic, Romania, Slo-
vakia, and UK). The study included male and femalesubjects
aged≥40years,withmoderate-to-severepaininducedbyOA
(as deﬁned by the American College of Rheumatology) of
the hip or knee. Moderate-to-severe OA pain was deﬁned as
am e a nw e e k l ys c o r eo f≥5 on a scale of 0–10 for “pain on
average” on the BPI scale, which was calculated as a mean
of the pain assessments collected at screening visit (week
−1), telephone call (week –0.5), and baseline visit (week 0).Pain Research and Treatment 3
Subjects must have suﬀered from chronic OA pain in the
target joint for more than 3 months, and their pain must
not have been adequately controlled with daily analgesic
(NSAIDs or paracetamol) treatment for the month before
beginning the study. Subjects were excluded from the study
for any of the following reasons: regular treatment with an
opioid in the 4 weeks before the screening visit—infrequent
use of tramadol, codeine, tilidine, or dihydrocodeine for no
more than 10 days in the 4 weeks before the screening visit
was acceptable, but subjects were to stop any use of weak
opioids at the screening visit, another type of continuous
p a i nt h a ts t o o do u ti nc o m p a r i s o nw i t hO Ap a i ns u c ha s
ﬁbromyalgia, cervical radiculopathy, or chronic low back
pain, any of the following 6 months before entering study:
major trauma to target joints, infection in target joints,
radiologically apparent avascular necrosis in target joints,
hyaluronan injections in the target joints, arthrodesis in the
year or arthroscopy in the 2 months before entering study,
planned treatment that could have altered the degree of pain
withinthestudyperiod,subjectswhowerebeingtreatedwith
buprenorphine, nalbuphine, or pentazocine; corticosteroid
injections in the 3 months before the start of the study.
Atthescreeningvisit(week–1),subjectstakingweakopi-
oids discontinued their medication; subjects taking NSAIDs
or paracetamol remained on a stable dose. Subjects were
randomised to receive either oral OROS hydromorphone
hydrochloride 4mg once daily or matched placebo; placebo
tablets were of identical appearance to the OROS hydromor-
phone hydrochloride tablets, that is matched for colour and
size. Treatment comprised a 4-week titration phase and a
12-week maintenance phase. In the event of unsatisfactory
pain control, subjects had their dose titrated 3-4 days after
randomisation until week 4 of the study with intervals of
at least 3-4 days between dose increments. Possible doses
were 4mg, 8mg, 12mg, 16mg, 24mg, and a maximum daily
dose of 32mg. There followed a 12-week maintenance phase
on as stable a dose as possible. If a dose of 32mg did not
provide suﬃcient analgesia, subjects were withdrawn owing
to lack of eﬃcacy and had their dose tapered oﬀ by reducing
their dose in speciﬁed increments every 2 days. At the end
of the double-blind treatment phase, subjects had their dose
tapered oﬀ to allow safe discontinuation of the study drug.
This tapering oﬀ phase also applied if subjects prematurely
discontinued.Paracetamolwasallowedasrescuemedication,
provided that a subject did not exceed the total permitted
daily dose (4g per day until day 8 and then 2g per day for
the remainder of the study).
Subjects returned to the clinic at 1, 2, 3, 4, 8, 12, and
16 weeks for scheduled assessments and were contacted by
telephone call between visits. All items of the BPI were used
to assess pain at screening, visit 1 (week 0), visit 5 (week
4), visit 6 (week 8), visit 7 (week 12), and visit 8 (week
16). Bodily pain, functional impairment, and stiﬀness were
assessed using the WOMAC OA index at visit 1 (week 0),
visit 5 (week 4), visit 6 (week 8), visit 7 (week 12), and visit
8 (week 16). HRQoL was assessed at visit 1 (week 0), visit 5
(week 4), visit 6 (week 8), visit 7 (week 12), and visit 8 (week
16) using the SF-36 HRQoL questionnaire. Quality of sleep
was assessed at visit 1 (week 0) and visit 8 (week 16) using
a MOS sleep subscale. AEs were monitored throughout the
study.
Subjects were randomly assigned to receive daily doses
of OROS hydromorphone hydrochloride or placebo in a
1:1 ratio based on a computer-generated randomisation
schedule prepared by an independent statistician (AJ). The
randomisation was balanced by using randomly permuted
blocks of subjects, with a block size of 4 and was stratiﬁed
by OA of the hip or knee; study sites received blocks of
study medication. There were two separate randomisation
lists; one corresponded to OA of the hip and the other to
OA of the knee. Each site received treatment kits for both
strata (hip and knee), and the investigators were instructed
to select the next available (consecutive) number for each
of the strata. If subjects had OA of both the hip and knee,
they were stratiﬁed according to whichever target joint was
predominantly painful. Based on these randomisation lists,
the study drug was packaged and labelled for the group of
subjects according to the target joint. Subject numbers were
preprintedonthestudydruglabels(distinctiveidentiﬁcation
numbers for hip and knee) and assigned as subjects qualiﬁed
for the study. The medication kits were labelled with a 2-
part tear-oﬀ label bearing information that met applicable
regulatory requirements. One part of the tear-oﬀ label was
attached to the subject’s drug-dispensing log when the drug
was dispensed. The investigator and the subject were blinded
to treatment allocation.
2.2. Statistical Methods
2.2.1. Sample Size Calculation. Ad i ﬀerence of 1 point in
“pain on average” on the BPI scale was considered to be a
clinically important diﬀerence [30]. Based on the results of
a previous study with OROS hydromorphone hydrochloride
in subjects with OA [31], assuming that three baseline
measures and seven post-baseline measures were collected,
and calculating the sample size using the “sampsi” command
in Stata version 8.2 (StataCorp, College Station, Texas) for
repeated measures, 81 subjects were required per group to
detect a diﬀerence of 1 point in the BPI measure with 90%
power at a signiﬁcance level of 5%. To allow for a dropout
rate of approximately 40%, the study planned to recruit 135
subjects per group (i.e., 270 in total).
A reassessment of the sample size was done, without
breaking the blind, when 50% of subjects were randomised
and approximately 40% of subjects had either completed
the study or dropped out. This analysis conﬁrmed the
assumptions of the sample size calculation.
2.2.2. Analysis Populations. The safety population included
all randomised subjects who received at least one dose of
study drug. The intent-to-treat (ITT) population was used
for eﬃcacy analyses. The ITT population excluded subjects
who had no post-baseline eﬃcacy data and included subjects
who discontinued early owing to lack of eﬃcacy or other
reasons.Theper-protocol(PP)populationwasasubgroupof
the ITT population that excluded subjects who discontinued
early and all subjects with major protocol deviations. This4 Pain Research and Treatment
population was used for supportive evidence for the eﬃcacy
analyses.
2.2.3. Primary and Secondary Endpoints. The primary eﬃ-
cacy endpoint was assessed by recording the subjects’ score
in “pain on average” measured on the BPI scale at each
study visit. Only data for the BPI collected at clinic visits
was used. The primary eﬃcacy endpoint was analyzed
using a mixed-model regression analysis (mixed model for
repeated measures (MMRM)), which took into account
the correlation among repeated measures within individual
subjects and allowed subjects with incomplete data (as a
result of early dropout) to contribute their existing data to
the analysis. The main model to test for the primary eﬃcacy
variable consisted of “pain on average” measured on the BPI
scale as repeated measurement variable, treatment groups,
time on study represented by the visit number, study joint,
and baseline “pain on average” value (the latest pre-study
treatmentassessment)asﬁxedeﬀects.Therandomeﬀectwas
the subject number.
Secondary eﬃcacy endpoints were the total score of the
WOMAC OA index (visits 1, 5, 6, 7, and 8), pain as assessed
using the pain subscales of the WOMAC OA index (visits 1,
5, 6, 7, and 8), pain as assessed using the pain subscales of
the HRQoL instrument SF-36 (visits 1, 5, 6, 7, and 8), pain as
assessed by “pain at its worst in the last 24 hours”, “pain at its
least in the last 24 hours”, and “pain right now” measured
o nt h eB P Is c a l e( v i s i t s1 ,5 ,6 ,7 ,a n d8 ) ,a l ls u b s c a l e s
except pain of the HRQoL instrument SF-36 (visits 1, 5, 6,
7, and 8), the functional impairment and stiﬀness subscales
of the WOMAC OA index (visits 1, 5, 6, 7, and 8), the MOS
sleep subscale (visits 1 and 8), the dropout rate due to AEs,
and the dropout rate due to ineﬃcacy. Safety assessment
was based on reported AEs, dropouts due to AEs, vital
sign measurements, and physical examinations. Secondary
endpoints and safety results were summarised descriptively.
AEs were coded using MedDRA dictionary version 11.0 (22
May 2008), and analyses were done using SAS Version 9.1.3.
2.2.4. Post Hoc Analyses. Post hoc analyses were done to try
to understand why the primary endpoint was not reached in
this study. These included concomitant medication analyses
toinvestigate,inanexploratorysense,theextenttowhichthe
primary objective of the study was compromised by use of
concomitant analgesic medication, speciﬁcally paracetamol
or NSAIDs. Analyses were done using Stata Version 9.2.
3. Results
3.1.SubjectsStudied. Theﬁrstsubjectattendedtheﬁrststudy
visit on 05 October 2007, and the last subject completed the
last study visit on 24 November 2008.
344 subjects were screened and 288 were randomised:
139 subjects to the OROS hydromorphone group and 149
subjects to the placebo group. The maintenance phase was
completed by 84 subjects in the OROS hydromorphone
group and 116 subjects in the placebo group. In both groups,
AE, ineﬃcacy, and withdrawal of consent were the most
common reasons for discontinuation of study treatment.
FlowofsubjectsthroughthestudyissummarisedinFigure1.
The mean (standard deviation [SD]) age of subjects was
65 (±10.2) years. There were more subjects with OA of the
knee (74%) than OA of the hip (26%). The baseline BPI,
WOMAC OA index, HRQoL, and MOS sleep subscale scores
results were similar for the OROS hydromorphone and
placebogroups.Demographyandbaselinecharacteristicsare
summarised in Table 1.
The median (range) daily dose of study medication
during the study, calculated from total dose used and the
number of days on treatment, was 12.2 (3–28)mg and
20.1 (4–29)mg in the OROS hydromorphone and placebo
groups, respectively.
3.2. Eﬃcacy. The study did not meet the primary objective
of showing superiority of OROS hydromorphone compared
withplaceboinitsanalgesiceﬀectinsubjectswithmoderate-
to-severe pain induced by OA of the hip or knee, as
measuredbymeanchangefrombaselinein“painonaverage”
measured on the BPI scale. The primary eﬃcacy analysis did
not show superiority of OROS hydromorphone compared
with placebo (diﬀerence −0.2365, 95% conﬁdence interval
−0.5357 to 0.0627; P = .1212). The factors “time on study”
and baseline “pain on average” score measured on the BPI
scale had a highly signiﬁcant eﬀect (P<. 001) on the
BPI scale “pain on average” score, which means baseline
pain severity and time treated with the study drug had an
inﬂuence on pain on average at endpoint; study joint (hip
or knee) had no signiﬁcant impact on the BPI scale “pain
on average” score. Mean change from baseline in “pain on
average” measured on the BPI scale score by time is shown
in Figure 2, and mean change from baseline to the end of the
maintenance phase is shown in see Table 2.
All secondary measures improved signiﬁcantly in both
groups from baseline to the end of the study. No statistically
signiﬁcant diﬀerence was found between treatment groups
for any of the secondary endpoints looked at (see Table 2).
More subjects dropped out owing to an AE in the OROS
hydromorphone group (25.9%; 36/139) than the placebo
group (4.7%; 7/149); many of the AEs leading to discon-
tinuation in the OROS hydromorphone group were typical
opioid-related side eﬀects, most commonly nausea and
constipation. Subjects in the placebo group (10.7%; 16/149)
more often dropped out owing to ineﬃcacy compared with
subjects in the OROS hydromorphone group (3.6%; 5/139).
3.3. Safety and Tolerability. The majority of TEAEs reported
during the study were of mild or moderate severity: 208/232
TEAEs in the OROS hydromorphone group and 103/109
TEAEs in the placebo group. The frequency of mild TEAEs
w a sc o m p a r a b l eb e t w e e nt r e a t m e n tg r o u p s ,3 5 %v e r s u s
30% of subjects in the OROS hydromorphone and placebo
group, respectively. Higher proportions of subjects reported
moderate and severe TEAEs in the OROS hydromorphone
group (33% moderate and 14% severe) compared with
p l a c e b o( 1 2 %m o d e r a t ea n d4 %s e v e r e ) .Pain Research and Treatment 5
Screened: 334 subjects
Randomised: 288 subjects
OROS hydromorphone: 139 subjects Placebo: 149 subjects
Not randomised: 56 subjects
Withdrew consent: 29
Screen failure: 13
Other reason: 12
Adverse event: 1
Lost to followup: 1
Completed: 84 subjects
Withdrawn: 55 subjects
Adverse event: 36
Withdrew consent: 11
Inefficacy: 5
Lost to followup: 1
Investigator decision: 1
Other reason: 1
Completed: 116 subjects
Withdrawn: 33 subjects
Inefficacy: 16
Withdrew consent: 8
Adverse event: 7
Investigator decision: 2
Figure 1: Flow of participants through the study.
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Figure 2: Mean change from baseline in BPI item 5 (pain on aver-
age)scorebytime(ITTpopulation).Endpointincludesﬁnalassess-
ments for subjects who discontinued before the end of the study.
TEAEs that were possibly, probably, or very likely related
to study drug were reported by 78% of subjects in the OROS
hydromorphone group and 37% of subjects in the placebo
group.Drug-relatedTEAEsweremostfrequentlyreportedin
the gastrointestinal disorders and nervous system disorders
body systems in both groups; the frequency of these drug-
related TEAEs was higher in the OROS hydromorphone
group compared with the placebo group. Concomitant
medications for the treatment of TEAEs were given to 48
(35%) subjects in the OROS hydromorphone group and
14 (9%) subjects in the placebo group. More subjects in
the OROS hydromorphone group than the placebo group
required treatment for drug-related constipation, nausea,
and vomiting. Laxatives were used by 19.4% of subjects in
the OROS hydromorphone group compared with 2.0% of
subjects in the placebo group, and antiemetics were taken
by 10.8% of subjects in the OROS hydromorphone group
compared with 1.3% of subjects in the placebo group.
One death (not considered related to study) occurred in
the placebo group, no deaths occurred in the OROS hydro-
morphone group. There were 19 serious TEAEs reported
during the study; 10 events occurred in 4 (2.9%) subjects in
the OROS hydromorphone group, and 9 events occurred in
7 (4.7%) subjects in the placebo group.
3.4. Post Hoc Analyses. Post hoc analyses were done to try to
determine the extent to which the primary objective of the
study was compromised by use of concomitant paracetamol
or NSAIDs.
Duringthestudy,almost100%ofsubjectsreceivedeither
NSAIDs or paracetamol either as concomitant medication or
as rescue medication (Table 3).
Post-baseline “pain on average” scores measured on
the BPI scale were lower throughout the study for OROS
hydromorphone compared with placebo in subjects not
taking concomitant NSAIDs (N = 51; Figure 3). Scores were
similarbetweengroupsinsubjectswhodidtakeconcomitant
NSAIDs (N = 236).
Post-baseline “pain on average” scores measured on the
BPI scale were lower throughout the study for OROS hydro-
morphone compared with placebo in subjects taking parac-
etamol(N = 49). Scoresweresimilar betweengroupsin sub-
jects who did not take concomitant paracetamol (N = 238).6 Pain Research and Treatment
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Mean BPI 5 score by concomitant NSAID use and treatment, ITT population
Figure 3: Mean BPI score item 5 (pain on average) by concomitant NSAID use and treatment (ITT population).
4. Discussion and Conclusions
Thisrandomised,double-blind,placebo-controlled,parallel-
group trial compared the analgesic eﬀect of ﬂexibly titrated
OROS hydromorphone hydrochloride and placebo in sub-
jects with moderate to severe pain induced by OA of the hip
orkneenotadequatelycontrolledbyprevioustreatmentwith
NSAIDs or paracetamol. The study included a high number
ofsubjectswithOAoftheknee;moresubjectswithOAofthe
knee than with OA of the hip were available for enrolment
into the study, possibly because total hip replacement is
performed more frequently than total knee replacement.
The study did not meet the primary objective of
showing superiority of OROS hydromorphone compared
with placebo in its analgesic eﬀect induced in subjects with
moderate-to-severe OA of the hip or knee. The mean change
from baseline in “pain on average” score on the BPI scale was
similar in both groups. All secondary eﬃcacy measures also
improved signiﬁcantly in both groups from baseline to the
end of the study; these included total score of the WOMAC
OA index, the pain subscale score of the WOMAC OA index,
the pain subscale score of the SF-36 and “pain at its worst in
the last 24 hours,” “pain at its least in the last 24 hours,” and
“pain right now” on the BPI scale. The response observed in
the placebo group may be explained by the placebo response
commonly observed in pain studies ([32, 33]). However, the
response in the OROS hydromorphone group was no better
than that observed for the placebo group; these ﬁndings may
be explained by a combination of the inclusion criteria and
the use of concomitant medications.
Subjects were using non-opioid analgesics and NSAIDs
before entering the study; based on expert scientiﬁc advice
and ethical considerations, concomitant and rescue medica-
tion were permitted in the study design. Although subjects’
pain was not adequately controlled with the concomitant
analgesics at inclusion, subjects in the placebo group had
a good response without side eﬀects, whereas subjects in
the OROS hydromorphone group got a good response with
side eﬀects. The strong placebo eﬀect observed suggests
that subjects may not have needed opioid treatment and
their pain score (and other assessment results) would
have improved with continued paracetamol and/or NSAID
treatment [34]. Indeed, almost 100% of all subjects were
treated with NSAIDs and/or paracetamol as concomitant
medication. Post hoc concomitant medication analyses
showed that in a subgroup of subjects taking NSAIDs,
pain scores were similar with OROS hydromorphone and
placebo treatment. In a subgroup of subjects not taking
NSAIDs,painscoreswerelowerwithOROShydromorphone
compared with placebo treatment. In a subgroup of subjects
using concomitant paracetamol, pain scores appeared to be
lower with OROS hydromorphone compared with placebo
treatment. A previous study found that once-daily OROS
hydromorphone was associated with eﬀective pain relief andPain Research and Treatment 7
Table 1: Demographics and baseline assessments of subjects in the
HOP trial (ITT population).
OROS
hydromorphone
N = 138
Placebo
N = 149
Demographics
Age (years); median
(range) 65.0 (43–85) 66.0 (40–87)
Sex; n (%)
Male 32 (23) 48 (32)
Female 106 (77) 101 (68)
Race; n (%)
Caucasian 138 (100) 149 (100)
Weight (kg); mean (SD) 84.4 (15.7) 82.0 (15.6)
Height (cm); mean (SD) 163.9 (9.6) 165.9 (8.6)
Body mass index (kg/m2);
mean (SD) 31.5 (5.6) 29.7 (5.0)
Most aﬀected joint; n (%)
Left knee 51 (37) 50 (34)
Right knee 54 (39) 58 (39)
Left hip 10 (7) 19 (13)
Right hip 23 (17) 22 (15)
Baseline assessments
BPI; mean (SD)
Pain at its worst in the
last 24h 7.8 (1.23)1 7.8 (1.06)4
Pain at its least in the
last 24h 4.6 (1.57)1 4.5 (1.50)4
Pain on average 6.6 (1.04)1 6.5 (0.94)5
Pain right now 6.4 (1.49)1 6.2 (1.67)6
WOMAC OA Index; mean
(SD)
Pain subscale 11.8 (2.63)2 11.5 (2.71)5
Functional impairment
subscale 41.2 (9.25)1 39.8 (9.46)4
Stiﬀness subscale 4.6 (1.28)2 4.3 (1.44)4
Total score 17.7 (3.40)3 16.9 (3.90)5
SF-36; mean (SD)
Pain subscale 27.7 (10.84)2 27.8 (11.01)6
Physical functioning
subscale 25.0 (12.57)1 27.8 (13.33)4
Social functioning
subscale 52.1 (20.82)1 52.0 (21.28)4
Mental health
subscale 58.5 (17.47)1 59.5 (18.32)4
Health transition
subscale 44.0 (13.74)1 43.0 (14.86)5
MOS sleep subscale
Index I score 38.6 (17.43)1 35.7 (17.14)
Index II score 39.9 (17.08)1 37.2 (16.89)
1137subjects; 2136subjects; 3135subjects; 4148subjects; 5147subjects; 6146
subjects. N, total number of subjects; SD, standard deviation; n,n u m b e ro f
subjects;BPI,briefpaininventory;h,hours;WOMACOA,WesternOntario,
and McMaster Universities Osteoarthritis; MOS, medical outcome study.
Table 2: Primary and secondary eﬃcacy variables in the HOP
trial: mean (standard deviation) change from baseline to end of
maintenance phase (ITT population).
OROS hydro-
morphone
N = 138
Placebo
N = 149
BPI
Pain on average –2.4 (2.1)1 –2.6 (2.3)5
Pain at its worst in the last 24h –2.4 (2.5)1 –2.7 (2.6)5
Pain at its least in the last 24h –1.7 (2.2)1 –1.6 (2.6)5
Pain right now –2.6 (2.6)1 –2.4 (2.7)6
W O M A CO AI n d e x
Pain subscale –3.74 (4.49)2 –3.86 (4.52)5
Functional impairment
subscale
–11.93
(13.17)1
–11.90
(14.35)6
Stiﬀness subscale –1.37 (1.85)2 –1.22 (1.84)6
Total score –5.36 (5.99)3 –5.16 (6.15)5
SF-36 pain subscale 17.50 (20.48)4 19.47 (23.50)7
HRQoL
Physical functioning subscale 13.59 (19.71)1 14.72 (24.08)6
Social functioning subscale 7.29 (23.42)1 9.55 (24.11)6
MOS Sleep Subscale
Index I score –5.77 (17.45)1 –5.65 (14.30)6
Index II score –6.20 (16.81)1 –6.98 (14.43)6
1132 subjects; 2131 subjects; 3130 subjects; 4129 subjects; 5143 subjects;
6144subjects; 7142subjects.BPI,briefpaininventory;h,hour;WOMAC
OA,WesternOntarioandMcMasterUniversitiesOsteoarthritis;HRQoL,
health-related quality of life; MOS, medical outcome study.
Table 3: Concomitant analgesic medication use in the HOP trial
(ITT population).
Treatment
OROS
hydromorphone Placebo Total
NSAID, n (%)
No 21 (15.22) 30 (22.13) 51 (17.77)
Yes 117 (84.78) 119 (79.87) 236 (82.23)
Total 138 (100) 149 (100) 287 (100)
Paracetamol, n (%)
No 114 (82.61) 124 (83.22) 238 (82.93)
Yes 24 (17.39) 25 (16.78) 49 (17.07)
Total 138 (100) 149 (100) 287 (100)
Any analgesic, n (%)
No 5 (3.62) 11 (7.38) 16 (5.57)
Yes 133 (96.38) 138 (92.62) 271 (94.43)
Total 138 (100) 149 (100) 287 (100)
ITT, intent-to-treat; NSAID, non-steroidal anti-inﬂammatory drug.8 Pain Research and Treatment
improved functionality in patients with chronic, moderate-
to-severe OA of the knee or hip [27].
Subject selection may also have contributed to the
outcomeofthisstudy.Thesubjectselectioncriteriausedmay
not have been stringent enough to ensure that only subjects
with truly chronic pain were included; the mean “pain on
average” score measured on the BPI scale was calculated
fromthreeassessmentsmadeduringaone-weekperiodfrom
the screening visit to the baseline visit. Therefore, although
subjects had suﬃcient pain severity to meet the inclusion
criteria in the week immediately before the study, they may
not have been experiencing pain from OA of that severity
for a long period of time. It is, therefore, possible that some
patients were experiencing a temporary exacerbation of
pain that would have subsided with or without treatment.
Comparison of the baseline WOMAC OA scores between
the HOP trial and two previous placebo-controlled opioid
studies suggest that the subjects in the HOP trial may have
been less aﬀected by their underlying illness compared
with subjects in the other trials. In a randomised, placebo-
controlled trial that recruited patients with OA requiring
jointreplacementandwithmoderate-to-severepainthathad
been adequately controlled by weak opioids, transdermal
fentanyl provided signiﬁcantly better pain relief compared
with placebo in patients even though previously prescribed
NSAIDs and simple analgesics were continued [35]. In
a study that recruited patients with chronic OA of the
knee or hip who had moderate-to-severe mean daily pain
intensity despite chronic use of stable doses of NSAIDs or
other non-steroidal, non-opioid therapies, once-daily OROS
hydromorphone was associated with eﬀective pain relief and
improved functionality [27]. Therefore, patients with more
severechronicpainmaybeneﬁtfromtreatmentwithopioids.
During the study, drug-related TEAEs were reported by
almost twice as many subjects in the OROS hydromorphone
group compared with the placebo group. In both groups, the
most frequently reported drug-related TEAEs were gastroin-
testinal and nervous system disorders; these events are com-
monly associated with opioids. No changes were observed in
the well-documented safety proﬁle of hydromorphone.
There is some limited evidence that starting with a low
dose of opioid and slowly titrating to a higher dose may be
advantageousforavoidingintolerablesideeﬀectswhenstart-
ing treatment with oxycodone, oxymorphone, or hydromor-
phone ([24–27]). The eﬃcacy and tolerability of once-daily
OROS hydromorphone and twice-daily ER oxycodone were
compared in a 6-week, randomised, open-label, parallel-
groupstudyinpatientswithchronic,moderate-to-severeOA
pain [27]. Patients received OROS hydromorphone initiated
at a dose of 8 mg once daily (n = 71) versus ER oxycodone
initiated at a dose of 10mg twice daily (n = 67). The
study consisted of a 14-day dose-titration and stabilisation
period and a 28-day maintenance period. The knee was the
aﬀected joint in 79.8% of participants. Comparable levels of
pain relief reductions in pain severity were observed. Some
improvements were evident early in the study, when patients
were receiving lower doses of analgesic. Dropouts due to
AEs were similar between treatment groups; 35.2% in the
hydromorphone group and 32.8% in the oxycodone group.
In conclusion, the primary objective of showing supe-
riority for OROS hydromorphone hydrochloride compared
withplaceboinitsanalgesiceﬀectinsubjectswithmoderate-
to-severe pain induced by OA of the hip or knee was not
met in this study. Secondary eﬃcacy endpoints were also
similar between the two treatment groups. Possible reasons
forfailureofthestudyarethatsubjectswerenotexperiencing
chronic moderate-to-severe pain or that their pain was
adequately treated with paracetamol and/or NSAIDs. No
changes were observed in the well documented safety proﬁle
of hydromorphone.
Before selecting patients with chronic OA pain for
treatment with opioids, we recommend that clinicians be
satisﬁed that pain is truly chronic and does not respond
to weaker analgesics. A report published by the European
leagueagainstrheumatism(EULAR)OAtaskforcenotesthat
opioid analgesics, with or without paracetamol, are useful
alternatives in patients in whom NSAIDs, including COX-
2 selective inhibitors, are contraindicated, ineﬀective, and/or
poorly tolerated [36].
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